Stata version 13

Manufactured by StataCorp

Sourced in United States, Denmark, Austria, United Kingdom

Stata version 13 is a software package designed for data analysis, statistical modeling, and visualization. It provides a comprehensive set of tools for managing, analyzing, and presenting data. Stata 13 offers a wide range of statistical methods, including regression analysis, time-series analysis, and multilevel modeling, among others. The software is suitable for use in various fields, such as economics, social sciences, and medical research.

Automatically generated - may contain errors

Lab products found in correlation

Sas version 9, by SAS Institute (52 mentions) Stata statistical software release 13, by StataCorp (29 mentions) R version 3, by R Project for Statistical Computing (16 mentions) Spss version 22, by IBM (12 mentions) Spss version 21, by IBM (11 mentions) Prism 5, by GraphPad (9 mentions) Sas version 9, by StataCorp (8 mentions) Spss version 20, by IBM (7 mentions) Prism 6, by GraphPad (6 mentions) Spss version 24, by IBM (6 mentions) Spss version 25, by IBM (6 mentions) Epidata version 3, by StataCorp (5 mentions) Stata 13, by StataCorp (5 mentions) Sas 9, by SAS Institute (5 mentions) Sas software version 9, by SAS Institute (4 mentions) Prism version 8, by GraphPad (3 mentions) Stata, by StataCorp (3 mentions) Spss statistics 21, by IBM (3 mentions) Stata statistical software, by StataCorp (3 mentions) Sas enterprise guide 7, by SAS Institute (3 mentions)

2 789 protocols using stata version 13

Network Meta-analysis of Metastatic Colorectal Cancer Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols

Data were analyzed with STATA version 13.0 software (StataCorp, College Station, Texas, USA). Three or more interventions were divided into all possible combinations of two intervention tests. Consistency or inconsistency testing was waived because of the absence of a closed-loop in the present network meta-analysis. The intergroup discrepancies for outcomes of PFS and OS were presented with hazard ratios (HRs), and the variance estimates were calculated from the reported confidence intervals (CIs). HRs of PFS and OS were used for indirect comparison with the random-effects model. The ORR, DCR, AEs, SAEs, and FAEs were calculated with the ORs. Indirect comparison of regorafenib, fruquintinib, TAS-102, and placebo, network meta-analysis methods (STATA network) were performed. Based on the surface under the cumulative ranking (SUCRA) curve, the efficacy and safety of the three drug treatments were ranked. Review Manager (RevMan) version 5.3 software (Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for the description of the PRISMA flow diagram [10 (link)], risk of bias summary, and risk of bias graph, while the other figures in the present study were developed with STATA version 13.0 software (StataCorp, College Station, Texas, USA). Publication bias of the literature was evaluated using funnel plots.

Chen J., Wang J., Lin H, & Peng Y. (2019). Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 25, 9179-9191.

+ Open protocol

+ Expand

Cardiac and Coronary Dose Correlations

Check if the same lab product or an alternative is used in the 5 most similar protocols

Correlation analyses between cardiac segment and whole heart doses, and between coronary artery segment and LV segment doses, were performed using STATA, version 13.2 (StataCorp, College Station, TX).

Duane F.K., McGale P., Brønnum D., Cutter D.J., Darby S.C., Ewertz M., Hackett S., Hall P., Lorenzen E.L., Rahimi K., Wang Z., Warren S, & Taylor C.W. (2019). Cardiac Structure Doses in Women Irradiated for Breast Cancer in the Past and Their Use in Epidemiological Studies. Practical Radiation Oncology, 9(3), 158-171.

+ Open protocol

+ Expand

Quality Indicators for Cervical Cancer Care

Check if the same lab product or an alternative is used in the 5 most similar protocols

Adherence to each QI and its 95% confidence interval (CI) were calculated. The analysis included all patients who received first-line treatment at the participating facility. Three QIs pertained to treatment for cervical intraepithelial neoplasia 3 (CIN3), 3 for stage III or IVA disease, and one QI for stage IVB cancer. One QI addressed the examination of the extent of cancer and another QI pertained to brachytherapy regardless of the stage.
All analyses were performed on Stata version 13.2 (StataCorp LP, College Station, TX, USA). This study protocol was approved by the Institutional Review Board of the National Cancer Center, Japan (approval No. 2013-081).

Watanabe T., Mikami M., Katabuchi H., Kato S., Kaneuchi M., Takahashi M., Nakai H., Nagase S., Niikura H., Mandai M., Hirashima Y., Yanai H., Yamagami W., Kamitani S, & Higashi T. (2018). Quality indicators for cervical cancer care in Japan. Journal of Gynecologic Oncology, 29(6), e83.

+ Open protocol

+ Expand

Statistical Analysis of Clinical Data

Check if the same lab product or an alternative is used in the 5 most similar protocols

Data were double-entered and validated in OpenClinica (http://www.openclinica.com). An in-house Query Management System developed by the Data Centre QMSPlus [23 (link)] was used to generate queries. All statistical analyses were performed using STATA version 13.2 (http://www.stata.com).
Continuous data at baseline were summarized using mean [standard deviation (SD)] and median [interquartile range (IQR)]. Binary and categorical data were summarized as raw numbers and percentages. Comparisons between subgroups were done using chi-square tests or ANOVA where applicable.

Kimutai R., Musa A.M., Njoroge S., Omollo R., Alves F., Hailu A., Khalil E.A., Diro E., Soipei P., Musa B., Salman K., Ritmeijer K., Chappuis F., Rashid J., Mohammed R., Jameneh A., Makonnen E., Olobo J., Okello L., Sagaki P., Strub N., Ellis S., Alvar J., Balasegaram M., Alirol E, & Wasunna M. (2017). Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. Clinical Drug Investigation, 37(3), 259-272.

+ Open protocol

+ Expand

Gender Differences in Infant Mortality

Check if the same lab product or an alternative is used in the 5 most similar protocols

We analysed data using Stata version 13.2 (StataCorp, College Station, TX, USA). We estimated the gender differences in mortality on the first day of life, and in first week of life, neonatal period and post-neonatal period (29–180 days and 181–365 days) in multiple logistic regression models taking the cluster design into account using the ‘xtlogit’ command in Stata. We included the clusters (PHC) as a random effect in these models. All socio-demographic and economic variables (mother’s education, mother’s occupation, caste, wealth quintile, place of birth, religion, distance from the PHC to nearest point on the highway) were included as covariates. The associations between gender and other socio-demographic and economic variables with mortality at different periods of infancy were analysed by including interaction terms in the logistic regression models. We also assessed whether there was multicollinearity between the covariates by estimating the variance inflation factors.

Chowdhury R., Taneja S., Mazumder S., Bhandari N, & Strand T.A. (2017). Gender differences in infant survival: a secondary data analysis in rural North India. BMJ Open, 7(8), e014179.

+ Open protocol

+ Expand

Pharmacist Attitudes and Contraception Provision

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used descriptive statistics to characterize the sample and evaluate contraceptive knowledge, motivation to participate in the program and perception of barriers to direct provision. We developed a logistic regression model to examine the association between years in pharmacy practice and intent to provide direct access to contraception. Our key independent variable was years of practice as a pharmacist. We estimated the odds of intent to provide HC by years in practice and included pharmacist and pharmacy-level covariates in all models. We selected covariates based on a literature review and our a priori assumptions about which covariates were likely to influence behavior. Survey questions were designed in part to capture pharmacist characteristics that were expected to influence behavior. We tested for interactions of potential moderators such as age, using the likelihood ratio test. Covariates included age, sex, urban/rural pharmacy location defined using zip code, and clinical services currently offered (e.g emergency contraception provision). Definitions for rural and urban locations were based on zipcode designations from the state of Oregon’s Office of Rural Health. All analyses were conducted in Stata version 13.2 (StataCorp LP, College Station, Texas, USA).

Rodriguez M.I., McConnell K.J., Swartz J, & Edelman A.B. (2016). Pharmacists prescription of hormonal contraception in Oregon: Baseline knowledge and interest in provision. Journal of the American Pharmacists Association : JAPhA, 56(5), 521-526.

+ Open protocol

+ Expand

Comparative Statistical Analysis in Stata

Check if the same lab product or an alternative is used in the 5 most similar protocols

We compared descriptive statistics using chi-square tests and T-tests as appropriate. We used Stata version 13.0 software (StataCorp Lt).

Houpy J.C., Lee W.W., Woodruff J.N, & Pincavage A.T. (2017). Medical student resilience and stressful clinical events during clinical training. Medical Education Online, 22(1), 1320187.

+ Open protocol

+ Expand

Systematic Review of CKD-Periodontal Disease Link

Check if the same lab product or an alternative is used in the 5 most similar protocols

All analyses were conducted by using DerSimonian-Laird random-effects and inverse variance model. Multivariable-adjusted risk estimates of dichotomous data were pooled and RRs were presented.
Chi-square test and I² inspection were carried out to determine the heterogeneity between included studies. I² > 50% or Q test P ≤ 0.1 were considered to be substantial heterogeneity.
Subgroup analysis was conducted to assess the effect of CKD stage (CKD stage 3–5, CKD 5D, and transplantation), adjustment for confounding variables, study design, study duration, regions, diagnostic criteria of periodontal disease, and reference population.
We performed sensitivity analyses by omitting individual studies stepwise and exploring the effect of individual studies on the overall estimates. Publication bias was evaluated by visual inspection of funnel plot symmetry and Egger’s regression test. All tests were 2-sided and P value <0.05 was considered statistically significant. All analyses were performed using STATA version 13.0 software (STATA Corp, College Station, Texas, USA).

Zhang J., Jiang H., Sun M, & Chen J. (2017). Association between periodontal disease and mortality in people with CKD: a meta-analysis of cohort studies. BMC Nephrology, 18, 269.

+ Open protocol

+ Expand

Chronic Kidney Disease Prevalence in Thailand

Check if the same lab product or an alternative is used in the 5 most similar protocols

Continuous data are presented as means ± SD. Categorical variables are presented as percent. The CKD prevalence (95% CI) estimates were probability-weighted for the registered 2014 Thai population stratified by age, sex, area of residence (urban/rural), and geographic region. Estimates of means and proportions were calculated for subgroups defined by characteristics of interest. We analyzed the association between risk factors and eGFR < 60 or CKDu with multivariable logistic regression models using No CKD as the comparator for all subjects, and CKDu2 and eGFR < 60 (DM-HT-Prot ≤ 1 +)_Age≥70, separately. Independent variables included age (per 10 years), sex, diabetes (yes/no), hypertension (yes/no), history of gout (yes/no), history of urinary stone (yes/no), taking pain killer (regular/occasional or none), urban/rural, BMI (< 18.5, 18.5– < 25 as reference,25– < 30, and ≥ 30 kg/m³), current smoking (yes/no), history of cardiovascular disease (CVD yes/no), and herbal medication use (yes/no). Missing data were excluded. All statistical analyses were performed using Stata version 13.0 software (StataCorp, College Station, TX, USA). The significance level was two-sided and P values were set at < 0.05.

Aekplakorn W., Chariyalertsak S., Kessomboon P., Assanangkornchai S., Taneepanichskul S., Neelapaichit N., Chittamma A, & Kitiyakara C. (2021). Women and other risk factors for chronic kidney disease of unknown etiology in Thailand: National Health Examination V Survey. Scientific Reports, 11, 21366.

+ Open protocol

+ Expand

Factors Influencing Hospital Vaccination Policies

Check if the same lab product or an alternative is used in the 5 most similar protocols

We calculated descriptive statistics for hospital characteristics (bed size, government-funded or private, teaching or non-teaching). The proportions for each vaccine and combination of vaccines implemented in hospitals' vaccination policies were also calculated. We examined the association between hospital characteristics and hospitals' vaccination policies using χ² tests. Factors associated with influenza vaccination coverage were also investigated using simple and multiple linear regression analyses. A P value < 0.05 was considered significant. Statistical analyses were performed using Stata version 13.0 software (Stata Corporation, College Station, TX, USA).

Park S.H., Lee M.S., Kim S.R, & Kwak Y.G. (2020). A Nationwide Survey on the Hospital Vaccination Policies in Korea. Journal of Korean Medical Science, 35(12), e76.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!